GlobeNewswire

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Share

Ad hoc announcement pursuant to Art. 53 LR

  • Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST

Allschwil, Switzerland – June 28, 2021
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).

An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, each year more than 800,000 persons living in the US will suffer a heart attack.[1]

Although the management of AMI has improved in recent decades, morbidity and mortality associated with AMI remain high. The majority of deaths occur outside the hospital.[2,3] Early action is crucial for survival and to preserve heart muscle.

Besides aspirin, there are no treatment options currently available for the critical time from onset of AMI symptoms to first medical contact. The development of selatogrel in an autoinjector aims to fulfill this medical gap: upon symptoms suggestive of a heart attack, patients would self-inject selatogrel as early as possible and immediately call for emergency medical help.

Martine Clozel, MD and Chief Scientific Officer at Idorsia, commented:
“From the moment that symptoms start, the clock is ticking. Thrombus formation is progressing, and ischemia is rapidly causing irreversible damage to the heart. In the initial stages of thrombus formation, platelet aggregation dominates – a process in which the platelet P2Y12 receptor plays a key role. If left untreated, the thrombus will become fibrin rich, at which point platelets have a more limited role in thrombus formation. This suggests that a fast-acting P2Y12 receptor antagonist could cut short the thrombus formation in the initial stages of thrombus formation. Our drug discovery team has created a compound with unique properties which might fill this important therapeutic gap.”

Dr Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, Professorof Medicine at Harvard Medical School, and Chair of the Steering Committee for SOS-AMI, commented:
“P2Y12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class.”

To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the potential to satisfy these necessary conditions.

Selatogrel administered subcutaneously is a potent, highly selective, fast-acting, reversible P2Y12 receptor antagonist. Two published Phase 2 studies, one in patients with chronic coronary syndromes and one in patients with AMI showed fast and reversible inhibition of platelet aggregation. Subcutaneous administration of selatogrel 16 mg has demonstrated a rapid onset of action, within 15 minutes, with the magnitude of the effect extending over approximately eight hours. Selatogrel was safe and well tolerated in both studies.[6,7]

About the Antares Pharma integrated drug delivery device
In late 2019, Idorsia entered into a global development agreement with Antares Pharma, a US-based leader in autoinjector and rescue pen technologies, to design and customize an autoinjector for selatogrel. The Antares autoinjector was selected for its robustness, reliability, ease-of-use and emergency-ready capabilities – key characteristics necessary due to the nature of AMI. Idorsia has confirmed the usability of the Antares autoinjector through human factor validation studies.

About Selatogrel Outcome Study in suspected Acute Myocardial Infarction SOS-AMI
Idorsia is initiating an international, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the clinical efficacy and safety of 16 mg selatogrel when self-administered (on top of standard-of-care) upon occurrence of symptoms suggestive of an acute myocardial infarction. The primary efficacy endpoint is the occurrence of death from any cause, or non-fatal AMI after any study treatment self-administration. The study will enroll approximately 14,000 patients who are at high risk of recurrent AMI, at around 250 sites in about 30 countries.

A Special Protocol Assessment has been agreed with the FDA. This indicates the FDA is in agreement with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints and planned analyses) for a study intended to support a future marketing application.

In December 2020, the FDA designated the investigation of selatogrel for the treatment of a suspected AMI in adult patients with a history of AMI as a “fast-track” development program. This designation is intended to promote communication and collaboration between the FDA and pharmaceutical companies for drugs that treat serious conditions and fill an unmet medical need.

Guy Braunstein, MD and Head of Global Clinical Development at Idorsia, added:
“Selatogrel has a pharmacokinetic and pharmacodynamic profile that results in a fast onset, and short duration of action - making it suitable for administration at the onset of symptoms. It is potent and highly selective for the P2Y12 receptor and was well-tolerated in the Phase 2 studies. Further to these properties, selatogrel is suitable for subcutaneous administration, giving rise to the real innovation in SOS-AMI: self-administration as early as possible after onset of symptoms of a suspected AMI. We are now ready to put selatogrel in the hands of patients and I am looking forward to seeing SOS-AMI progress in the course of the next 2-3 years.”

SOS-AMI has been designed as a patient-centric study in collaboration with patients. Patients participating in SOS-AMI will be trained by qualified professionals appointed at each study site, on how to recognize AMI symptoms, on how and where to self-inject treatment, and to call for emergency medical help immediately. Trainers will use standardized material mirrored across all countries, which has been developed with the support of education experts, feed-back from post-MI patients, and in alignment with current guidelines. The patient is empowered through focused education to take action. In addition, regular interaction is performed by telephone with the designated site trainer, minimizing the burden on the patient, particularly during times of a global pandemic.

Dr Mary Mooney,Assistant professor at the School of Nursing and Midwifery, Trinity College Dublin, and Member of the Steering Committee for SOS-AMI, commented:
“I am passionate about patient education and involving patients in their own care. SOS-AMI pushes the boundaries of heart attack care provision. It puts the patient at the center of the study and empowers them to manage their heart attack symptoms. This means that our success will be heavily dependent on patients’ responses, but I believe patients are ready for this challenge. For our part, we are educating patients on how to recognize the symptoms of AMI, how to use the study autoinjector, and to call emergency services after using the study autoinjector. We should strive for a world where slowing or stopping of a heart attack is as simple as a self-injection. We know the potential is there, we just need to see if it can be realized.”

Jean-Paul Clozel, MD and Chief Executive Officer, concluded:
“Self-administration is currently used to treat a number of emergent medical conditions – why not AMI? Anyone can have a good idea, but drug innovation happens when a great team with a great compound, takes a great idea and runs with it. With our integrated drug delivery device, the potential to self-administer selatogrel in the critical time period immediately following onset of suspected AMI symptoms could be revolutionary for patients.”

Notes to the editor

Investor webcast
An investor conference call and webcast will be held to discuss the Phase 3 program. The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers).

Date:        Monday June 28, 2021
Time:        14:30 CEST | 13:30 BST | 08:30 EDT

Webcast participants should visit Idorsia’s website www.idorsia.com 10-15 minutes before the webcast is due to start.
Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial-in:        CH: +41 44 580 6522 | UK: +44 20 3009 2470 | US: +1 877 423 0830
PIN:            27481532#

About acute myocardial infarction (AMI)
An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off. It is usually caused by a blood clot or blockage in one or more of the coronary vessels supplying blood to the heart muscle. An AMI requires immediate treatment and medical attention, as any delay in intervention can result in irreversible damage to the heart muscle. According to the US Centers for Disease Control and Prevention, each year more than 800,000 persons living in the US will suffer a heart attack.[1]

The need for an early intervention has been highlighted by the guidelines of the European Society of Cardiology, which identified the prehospital phase as the most critical for high-risk patients and reiterated that efforts must be made to reduce the delay in initiation of treatment in order to reduce death.[4,5]

Data supporting selatogrel in suspected AMI
Idorsia has completed a multicenter, double blind, randomized, placebo-controlled study assessing the pharmacodynamics, pharmacokinetics, tolerability and safety of a single subcutaneous injection of selatogrel in adults with chronic coronary syndrome. In this study, 346 patients receiving conventional background oral antiplatelet therapy (e.g. acetylsalicylic acid, P2Y12 receptor antagonists) were randomized to receive either selatogrel 8 mg, 16 mg or placebo. The primary objective of the study was to characterize inhibition of platelet aggregation relative to placebo after a single subcutaneous injection of selatogrel either in the thigh or in the abdomen at 2 different doses in patients with chronic coronary syndromes.[6]

Idorsia has also completed a multi-center, open-label, randomized, exploratory study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of selatogrel in adults with acute myocardial infarction. In this study, 48 patients with confirmed diagnosis of AMI and time from onset of symptoms of more than 30 min and less than 6 hours were randomized to receive either selatogrel 8 mg or 16 mg in addition to conventional antithrombotic treatment (e.g., acetylsalicylic acid, oral P2Y12 receptor antagonists, anticoagulants). The primary objective of the study was to assess the inhibition of platelet aggregation 30 minutes after a single subcutaneous injection of selatogrel in patients with AMI.[7]

About P2Y12 receptor antagonism
Platelet adhesion, activation and aggregation play a pivotal role in atherothrombosis. An essential element in the platelet activation process is the interaction of adenosine diphosphate (ADP) with the platelet P2Y12 receptor. This platelet activation and aggregation can be inhibited by antagonizing the platelet P2Y12 receptor. This prevents the binding of ADP
to the receptor, which reduces platelet aggregation and the reaction of platelets to stimuli of thrombus aggregation.

About DrDeepakL. Bhatt
Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.

After graduating as valedictorian from Boston Latin School, Dr Bhatt obtained his undergraduate science degree as a National Merit Scholar at MIT while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master of Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System and served in that role for several years. He was a Senior Investigator in the TIMI Study Group for over a decade. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He has been listed in Best Doctors in America from 2005 to 2020. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.

Dr Bhatt has authored or co-authored over 1650 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2020. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is Senior Associate Editor for News and Clinical Trials for ACC.org. He is the Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. Dr Bhatt receives funding paid to Brigham and Women’s Hospital from Idorsia for his role as the Chair of the Steering Committee for SOS-AMI.

About Dr Mary Mooney
Dr Mary Mooney (PhD, MSc, RGN, RM, RNT, MA, Higher. Diploma Cardiovascular Studies) is an assistant professor in the School of Nursing and Midwifery, Trinity College Dublin. Her research areas focus predominantly on cardiac-related aspects of patient care and nurse education. Her research experience encompasses qualitative and quantitative research methods, including randomized controlled trials. Mary’s PhD was a randomized controlled trial that comprised delivering an educational intervention to patients with Acute Coronary Syndrome. This Health Research Board (HRB) funded study was the first RCT in the world to target and successfully reduce patient pre-hospital delay time and its groundbreaking effect has been renowned for its effectiveness in reducing patient delay in the presence of heart attack symptoms. Dr Mooney has many publications, is widely cited, and her work has contributed to the development of further international research with which she is currently actively engaged.

In terms of research funding, Mary has been Principal Investigator or a co-applicant across a range of projects, from a variety of funding sources. She has wide national and international collaborates with whom she is actively engaged in research. Mary maintains a clinical remit in cardiology, in addition to her academic role, and is an external examiner for post-graduate programs in other universities. As an elected committee member for the Irish Nurses Cardiovascular association (INCA), she contributes to the delivery of cardiovascular education of nurses in Ireland. She is actively engaged in research, most of which is concerned with cardiovascular or critical care. She has worked as a researcher and clinical advisor to an Irish Enterprise, funded by Enterprise Ireland She has been an invited speaker and presenter across a range of national and international events. Dr Mooney serves as a consultant to Idorsia.

About Antares Pharma Inc.(NASDAQ: ATRS)
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies.

Key literature

  1. Benjamin EJ, et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation 2019;139(10):e56-e528.
  2. Adnet F, et al. Incidence of acute myocardial infarction resulting in sudden death outside the hospital. Emerg Med J. 2011;28(10):884–6.
  3. Norris RM. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. BMJ 1998;316(7137):1065–70.
  4. Ibanez B, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39(2):119–77
  5. Neumann FJ, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40(2):87–165
  6. Storey R. F, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2019;0, 1-9, doi:10.1093/eurheartj/ehz807
  7. Sinnaeve P, et al. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020 May 26;75(20):2588-2597. doi: 10.1016/j.jacc.2020.03.059. PMID: 32439008.
  8. Juif P, et al. Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects. The Journal of Clinical Pharmacology 2019, 59(1): 123-130. doi:10.1002/jcph.1296

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Beter Bed Holding announces the issue of 946,167 new ordinary shares23.7.2021 18:00:00 CEST | Press release

Beter Bed Holding N.V. (“BBH” ISIN NL0000339703), the Netherlands’ leading sleep specialist in retail, wholesale and B2B, announces the issue of 946,167 new ordinary shares of the Company against an issue price of € 6.82. The issue of shares is meant to remediate the impact on the Company’s solvency from the repayment of the perpetual loan, as announced in the interim results press release dated 21 July 2021. The net proceeds of the Offering will be used to strengthen our financial position and to provide the Company with the financial flexibility to accelerate the execution of its growth strategy 2025 as presented during the AGM of 12 May 2021. The increased attention for health and well-being, due to COVID-19, is expected to lead to increased demand for quality sleep as one of the three pillars of health. The investment program driven by our strategy is starting through the launch of a new shop format, subscription label Leazzzy, investments in data analytics and acceleration of onli

Arcadis reports transactions under its current share buyback program23.7.2021 12:00:00 CEST | Press release

Amsterdam, July 23, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 91.282 of its own shares in the period from 16 July up to and including 22 July 2021 at an average price of €34.59. The consideration of this repurchase was €3.2 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.0 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is the leading global desig

Vaisala Corporation Half Year Financial Report January–June 202123.7.2021 08:00:00 CEST | Press release

Vaisala Corporation Half Year Financial Report July 23, 2021 at 9.00 a.m. (EEST) Vaisala Corporation Half Year Financial Report January–June2021 Excellent growth continued in second quarter Secondquarter 2021 highlights Orders received EUR 120.1 (95.9) million, increase 25%Order book at the end of the period EUR 165.3 (145.3) million, increase 14%Net sales EUR 109.5 (91.4) million, increase 20%Operating result (EBIT) EUR 10.9 (7.9) million, 10.0 (8.7) % 0f net salesEarnings per share EUR 0.25 (0.16)Cash flow from operating activities EUR 11.1 (-1.1) million January–June 2021 highlights Orders received EUR 226.3 (185.6) million, increase 22%Net sales EUR 201.5 (178.6) million, increase 13%Operating result (EBIT) EUR 19.0 (13.1) million, 9.5 (7.3) % 0f net salesEarnings per share EUR 0.43 (0.27)Cash flow from operating activities EUR 29.4 (4.2) million Market development and businessoutlook for 2021 Market for high-end industrial instruments is expected to continue growth after strong re

FLOW TRADERS Q221 RESULTS23.7.2021 07:30:00 CEST | Press release

FLOW TRADERS Q221 RESULTS Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q221 results and 2021 Half Year report. Highlights Market ETP Value Traded decreased 14% quarter-on-quarter and decreased 14% H121 vs H120Flow Traders ETP Value Traded decreased 15% quarter-on-quarter and decreased 6% H121 vs H120Flow Traders recorded NTI of €94.4m in Q221 reflecting a more normalised market environment. This compares to NTI of €142.2m in Q121 and €229.9m in Q220. H121 NTI was €236.6m vs €724.8m in H120Total operating expenses of €54.1m incurred in Q221 which includes €0.6m of one-off COVID-19 and business continuity plan-related expenses577 FTEs as at 30 June 2021 compared to 566 FTEs as at 31 March 2021Q221 EBITDA reached €40.3m with a margin of 43% contributing to H121 EBITDA of €119.6m with a margin of 51%Q221 Net Profit amounted to €28.7m with basic EPS of €0.66. H121 Net Profit amounted to €90.2m with basic EPS of €2.05IFR/IFD came into force on 26 Ju

Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million23.7.2021 07:00:00 CEST | Press release

Press Release July 23, 2021 Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million Second quarter 20211 Signify's installed base of connected light points increased from 83 million in Q1 21 to 862 million in Q2 21 Sales of EUR 1,609 million; 9.6% nominal sales growth and CSG of 14.1%LED-based sales represented 82% of total sales (Q2 2020: 80%)Adj. EBITA margin improved by 190 bps to 10.9%Net income increased to EUR 82 million (Q2 20: EUR 81 million)Free cash flow of EUR 104 million (Q2 20: EUR 158 million)Net debt/EBITDA ratio of 1.7x (Q2 20: 2.4x) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s second quarter 2021 results. “In the second quarter we saw an acceleration of the pace of recovery in comparison to the first three months of the year. We successfully executed our strategy as demand for our connected lighting offers and our growth pla

Norsk Hydro: Andre kvartal 2021 – Rekordresultater og fortsatt positivt markedssentiment23.7.2021 07:00:00 CEST | Pressemelding

Norsk Hydro ASA rapporterte en justert EBITDA på 6.598 millioner kroner i andre kvartal 2021, en økning fra 2,794 millioner kroner i samme kvartal i fjor. Fortsatt oppgang i verdensøkonomien bidrar til økt etterspørsel etter aluminium og aluminiumprodukter. Forretningsområdene Hydro Aluminium Metal og Hydro Extrusions rapporterte rekordresultater for kvartalet. Rekordresultat i Aluminium Metal på grunnlag av økte priser og produktpremier på LMERobust drift, forbedringsprogrammet foran skjema Sterke prestasjoner i Extrusions og framdrift i vekstprosjekterStyrking av bærekraftposisjon med investeringer for vekst i resirkuleringSalget av forretningsområdet Hydro Rolling til KPS Capital Partners fullført Høyere all-in metallpriser og volumer i Aluminium Metal, bedre marginer og volumer i Extrusions og bedre resultater fra Hydro Energy bidro positivt til justert EBITDA. Disse positive elementene ble delvis utliknet av høyere råvarekostnader oppstrøms og negative valutaeffekter. Den globale

Norsk Hydro: Second quarter 2021 - Record results and continued positive market sentiment23.7.2021 07:00:00 CEST | Press release

Norsk Hydro ASA posted second-quarter 2021 adjusted EBITDA of NOK 6,598 million, up from NOK 2,794 million in the same quarter last year. Continued global economic recovery is supporting increased demand for aluminium and aluminium products. Hydro Aluminium Metal and Hydro Extrusions business areas reported record quarterly results. Record result in Aluminium Metal supported by LME prices and premiumsRobust operations, improvement program ahead of plan Strong performance in Extrusions and progress on growth initiativesStrengthening sustainability position with growth investments in recyclingSale of Hydro Rolling business area to KPS Capital Partners completed Higher all-in metal prices and volumes in Aluminium Metal, improved margins and volumes in Extrusions, and better results from Hydro Energy contributed positively to adjusted EBITDA. These positive elements were partly offset by higher raw material costs upstream and negative currency effects. The second quarter saw a continuation